$24.6
Pfizer


Performance
Dividends
1W
1M
YTD
1Y
3Y
7/36
Growth
Score
6/36
Dividend
Score
Valuation
PE Ratio
17.74
PS Ratio
2.24
RSI
-
0
PEG Ratio
0
1
PRG Ratio
1.33
PDG Ratio
0
Growth
2023
2024
2025*
2026*
3
Revenue
Revenue
*Analyst estimated growth
Fundamentals
3
Rule
of 40
66.36%
2
Gross Margin
67.39%
1
Current Ratio
1.26
Return on Assets
3.78%
Return on Equity
8.78%
Return on inv. Capital
8.97%
Dividend Growth
2023
2024
2025*
2
*Estimated growth
Dividends
Yield
6.91%
Per Year
4x
Payout Ratio
121.75%
Institutional Holder
Shares
Holders
Financials
Yealy
Quarterly
Revenue 2024 63.63B
2018
2019
2020
2021
2022
2023
2024
6
Net Income 2024 8.05B
2018
2019
2020
2021
2022
2023
2024
6
Gross Profit 2024 47.21B
2018
2019
2020
2021
2022
2023
2024
6
Events

PFE
Pfizer
in 277 days
before market open
Earnings per Share is expected with - and revenue with - .

PFE
Pfizer
in 193 days
before market open
Earnings per Share is expected with - and revenue with - .

PFE
Pfizer
in 95 days
before market open
Earnings per Share is expected with - and revenue with - .
About
Sector/Industry
Healthcare
Drug Manufacturers - General
IPO Date
01.06.1972
MaketCap
139.80B
Country
US
CEO
Albert Bourla
Description
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Updated 16.07.2025